Workflow
Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics
拜玛林制药拜玛林制药(US:BMRN) ZACKS·2025-10-28 07:01

BioMarin Pharmaceutical (BMRN) reported 776.13millioninrevenueforthequarterendedSeptember2025,representingayear−over−yearincreaseof4.1776.13 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.1%. EPS of 0.12 for the same period compares to 0.91ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof0.91 a year ago.The reported revenue compares to the Zacks Consensus Estimate of 784.4 million, representing a surprise of -1.05%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue and ...